| CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma | |
| Zhang, Tengyue; Ma, Kelong; Huang, Jin; Wang, Shitang; Liu, Yabei; Fan, Gaofei; Liu, Miao; Yang, Guangshan; Wang, Cheng; Fan, Pingsh 更多 | |
| 刊名 | ONCOTARGET
 |
| 2017 | |
| 卷号 | 8期号:66页码:110052-110063 |
| 关键词 | hepatocellular carcinoma (HCC) verapamil (VER) doxorubicin (ADM) CDKN2B chemotherapy resistance |
| DOI | 10.18632/oncotarget.22123 |
| URL标识 | 查看原文 |
| 公开日期 | [db:dc_date_available] |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/4595750 |
| 专题 | 山东大学 |
| 作者单位 | 1.Shandong Univ, Sch Clin Med, Jinan 250100, Shandong, Peoples R China. 2.[Zhang, Tengyue 3.Huang, Jin 4.Liu, Yabei 5.Fan |
| 推荐引用方式 GB/T 7714 | Zhang, Tengyue,Ma, Kelong,Huang, Jin,et al. CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma[J]. ONCOTARGET,2017,8(66):110052-110063. |
| APA | Zhang, Tengyue.,Ma, Kelong.,Huang, Jin.,Wang, Shitang.,Liu, Yabei.,...&Fan, Pingsh 更多.(2017).CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma.ONCOTARGET,8(66),110052-110063. |
| MLA | Zhang, Tengyue,et al."CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma".ONCOTARGET 8.66(2017):110052-110063. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论